Urinary Retention in Patients with BPH Treated with Finasteride or Placebo Over 4 Years

April 2000 in “ European Urology ”

Claus G. Roehrborn, Reginald C. Bruskewitz, G.C. Nickel, S. Glickman, C. A. Cox, R. Rox Anderson, Stanley J. Kandzari, R Herlihy, G. Kornitzer, B.T. Brown, H. Logan Holtgrewe, A. J. Taylor, Dayong Wang, Joanne Waldstreicher

finasteride BPH prostate volume PSA levels Propecia

Studysummary In this study, significantly fewer men treated with finasteride for moderate to severe BPH symptoms experienced acute urinary retention or required subsequent BPH-related surgery compared to placebo-treated patients.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

A study of 3,040 men with BPH symptoms and enlarged prostate glands found that finasteride reduces the risk of acute urinary retention and BPH-related surgery by 57% and 55%, respectively, compared to placebo over a period of 4 years. The study highlights the need for early intervention in managing BPH to prevent complications and improve quality of life. Prostate volume and PSA levels are significant factors in predicting urinary retention and surgery in patients who do not take finasteride.

View this study on karger.com →

Discuss this study in the Community →

Research cited in this study

1 / 1 results

The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia

research The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia

1054 citations , February 1998 in “The New England Journal of Medicine”

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.